News
Aridis Is Enrolling Patients in Pivotal Trial of Its Antibiotic-resistant Pneumonia Therapy Aerucin
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody...
News
KALYDECO® ( ivacaftor ) Approved By FDA For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function...
Vertex Pharmaceuticals Incorporated announced that the U.S. FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with CF ages 2 and older who have one of five residual function mutations that result in a splicing defect...
News
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma
Eisai Co., Ltd. announced that it has submitted applications to the US FDA and the EMA for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). This follows...
News
Lack Of Confidence In Serialization Preparations Highlighted By New Research
More than one third (40 per cent) of pharmaceutical industry professionals are not confident that they will meet serialization deadlines in the US and Europe, according to new industry research. As the FDA has announced plans...
News
Broad range of multifunctional mineral excipients
At CPhI in Frankfurt, Omya will showcase its Omyapharm® multifunctional excipient platform based on functionalized calcium carbonate, a highly structured mineral. Omyapharm® is suitable for numerous applications, including solid oral dosage forms such as conventional tablets...
News
Technology adoption fuels growth for pharma tech firm
Zenith Technologies has strengthened its global workforce, recruiting 100 people over the past year in response to growing demand for manufacturing execution system (MES) and automation technology in the pharma sector. The global life science technology...
News
Onyx helps accelerate TopiVert’s compounds to clinic
BRITISH biotech business TopiVert has recently initiated clinical trials with two of its narrow spectrum kinase inhibitor (NSKI) drug candidates following support from Onyx Scientific. The contract research organisation (CRO) and small scale API specialist has...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















